{"id":3674,"date":"2021-05-18T10:22:15","date_gmt":"2021-05-18T10:22:15","guid":{"rendered":"http:\/\/www.enyopharma.com\/fr\/?p=3674"},"modified":"2021-06-22T13:10:55","modified_gmt":"2021-06-22T13:10:55","slug":"hbv-tag-conference-2021-sponsorship","status":"publish","type":"post","link":"https:\/\/www.enyopharma.com\/fr\/hbv-tag-conference-2021-sponsorship\/","title":{"rendered":"HBV-TAG Conf\u00e9rence 2021 (Sponsorship)"},"content":{"rendered":"<p>11-12 Juin 2021<br \/>\nConf\u00e9rence virtuelle<\/p>\n<p>ENYO Pharma a sponsoris\u00e9 la conf\u00e9rence inaugurale virtuelle sur l&#8217;h\u00e9patite B &#8211; agents th\u00e9rapeutiques de 2021.<br \/>\n<a href=\"http:\/\/www.hbv-tag.org\" rel=\"noopener\" target=\"_blank\">www.hbv-tag.org<\/a><br \/>\n\u201cThe primary objective of the Virtual HBV-TAG Conference is to meet the educational needs of research and development stakeholders and healthcare professionals who seek to improve the lives of patients with HBV. The aim of the HBV-TAG conference is to bring together key opinion leaders from the teams of clinicians that care for patients with HBV (hepatologists and gastroenterologists) and pharmaceutical industry representatives to discuss optimized trial design, patient populations, therapeutic endpoints, as well as the potential benefits these agents can have for patients with HBV. This conference will deliver a focused scientific educational update that highlights the most clinically relevant advances in HBV to guide future directions in diagnostic procedures and the development of therapeutic agents for HBV.&#8221;<\/p>\n<p>Notre stand d&#8217;exposition virtuelle nous a permis de pr\u00e9senter des r\u00e9sultats pr\u00e9liminaires de notre compos\u00e9 phare Vonafexor (EYP001, FXR agonist) dans une \u00e9tude de Phase 2a traitant des patients na\u00effs souffrant d&#8217;une h\u00e9patite B chronique :<\/p>\n<p><center><br \/>\n<iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/Sicq2WUuaJU\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen><\/iframe><br \/>\n<\/center><\/p>\n","protected":false},"excerpt":{"rendered":"<p>11-12 Juin 2021<br \/>\nConf\u00e9rence virtuelle<\/p>\n<p>ENYO Pharma a sponsoris\u00e9 la conf\u00e9rence inaugurale virtuelle sur l&#8217;h\u00e9patite B &#8211; agents th\u00e9rapeutiques de 2021.<br \/>\n<a href=\"http:\/\/www.hbv-tag.org\" rel=\"noopener\" target=\"_blank\">www.hbv-tag.org<\/a><br \/>\n\u201cThe primary objective of the Virtual HBV-TAG Conference is to meet the educational needs of research and development stakeholders and healthcare professionals who seek to improve the lives of patients with HBV. The aim of the HBV-TAG conference is to bring together key opinion leaders from the teams of clinicians that care for patients with HBV (hepatologists and gastroenterologists) and pharmaceutical industry representatives to discuss optimized trial design,<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/www.enyopharma.com\/fr\/hbv-tag-conference-2021-sponsorship\/\">Lire la suite&nbsp;&raquo;<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-3674","post","type-post","status-publish","format-standard","hentry","category-events-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"editorENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/editorenyopharma\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.enyopharma.com\/fr\/category\/events-fr\/\" rel=\"category tag\">\u00c9v\u00e9nements<\/a>","rttpg_excerpt":"11-12 Juin 2021 Conf\u00e9rence virtuelle ENYO Pharma a sponsoris\u00e9 la conf\u00e9rence inaugurale virtuelle sur l&#8217;h\u00e9patite B &#8211; agents th\u00e9rapeutiques de 2021. www.hbv-tag.org \u201cThe primary objective of the Virtual HBV-TAG Conference is to meet the educational needs of research and development stakeholders and healthcare professionals who seek to improve the lives of patients with HBV. The&hellip;","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=3674"}],"version-history":[{"count":5,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3674\/revisions"}],"predecessor-version":[{"id":3825,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3674\/revisions\/3825"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=3674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=3674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=3674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}